Evotec, Shionogi Enter Drug Discovery Pact

Evotec AG and Shionogi & Co Ltd. have entered a fragment-based drug discovery alliance to identify small molecule modulators of various protein-protein interaction targets selected by Shionogi. Evotec will apply its integrated fragment-based drug discovery platform, EVOlution. The platform, used for the selection of target-specific strategies, combines biochemical and biophysical techniques including nuclear magnetic resonance
(NMR), surface plasmon resonance (SPR) and X-ray crystallography. Financial details were not disclosed.

Dr. Mario Polywka, chief operating officer of Evotec said, “We are extremely pleased that Shionogi
has decided to undertake these projects with Evotec. Our proprietary fragment-
based drug discovery platform has shown that it adds significant value to our partner´s programs and we look forward to supporting Shionogi in finding novel treatments for inflammation and infectious diseases.”